ArticleContemporary clinical trials communications2019

Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers.

Jim Murray et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.